We also found that PLD1 and phospho-Akt are coexpressed in some breast tumours, a fact which could complicate the utility of rapamycin-based therapies, as patients expressing both proteins could differ in sensitivity to mTOR inhibitors. This evidence concerns the gene AKT1 and breast neoplasm.